Nanoviricides Stock Net Income
| NNVC Stock | USD 1.08 0.03 2.70% |
As of the 29th of January, NanoViricides secures the Mean Deviation of 4.28, risk adjusted performance of (0.06), and Standard Deviation of 5.83. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of NanoViricides, as well as the relationship between them.
NanoViricides' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing NanoViricides' valuation are provided below:NanoViricides does not presently have any fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. NanoViricides | Build AI portfolio with NanoViricides Stock |
Will Stock sector continue expanding? Could NanoViricides diversify its offerings? Factors like these will boost the valuation of NanoViricides. Anticipated expansion of NanoViricides directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every NanoViricides data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding NanoViricides requires distinguishing between market price and book value, where the latter reflects NanoViricides's accounting equity. The concept of intrinsic value—what NanoViricides' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push NanoViricides' price substantially above or below its fundamental value.
It's important to distinguish between NanoViricides' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding NanoViricides should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, NanoViricides' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
NanoViricides 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to NanoViricides' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of NanoViricides.
| 10/31/2025 |
| 01/29/2026 |
If you would invest 0.00 in NanoViricides on October 31, 2025 and sell it all today you would earn a total of 0.00 from holding NanoViricides or generate 0.0% return on investment in NanoViricides over 90 days. NanoViricides is related to or competes with Verrica Pharmaceuticals, Jasper Therapeutics, SAB Biotherapeutics, Generation Bio, Evaxion Biotech, India Globalization, and Q32 Bio. NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes ... More
NanoViricides Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure NanoViricides' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess NanoViricides upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.11) | |||
| Maximum Drawdown | 34.35 | |||
| Value At Risk | (8.20) | |||
| Potential Upside | 7.69 |
NanoViricides Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for NanoViricides' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as NanoViricides' standard deviation. In reality, there are many statistical measures that can use NanoViricides historical prices to predict the future NanoViricides' volatility.| Risk Adjusted Performance | (0.06) | |||
| Jensen Alpha | (0.62) | |||
| Total Risk Alpha | (1.10) | |||
| Treynor Ratio | (1.50) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of NanoViricides' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
NanoViricides January 29, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.06) | |||
| Market Risk Adjusted Performance | (1.49) | |||
| Mean Deviation | 4.28 | |||
| Coefficient Of Variation | (1,005) | |||
| Standard Deviation | 5.83 | |||
| Variance | 33.99 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.62) | |||
| Total Risk Alpha | (1.10) | |||
| Treynor Ratio | (1.50) | |||
| Maximum Drawdown | 34.35 | |||
| Value At Risk | (8.20) | |||
| Potential Upside | 7.69 | |||
| Skewness | 1.36 | |||
| Kurtosis | 3.62 |
NanoViricides Backtested Returns
NanoViricides has Sharpe Ratio of -0.0937, which conveys that the firm had a -0.0937 % return per unit of risk over the last 3 months. NanoViricides exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify NanoViricides' Standard Deviation of 5.83, mean deviation of 4.28, and Risk Adjusted Performance of (0.06) to check out the risk estimate we provide. The company secures a Beta (Market Risk) of 0.39, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, NanoViricides' returns are expected to increase less than the market. However, during the bear market, the loss of holding NanoViricides is expected to be smaller as well. At this point, NanoViricides has a negative expected return of -0.55%. Please make sure to verify NanoViricides' potential upside, as well as the relationship between the daily balance of power and market facilitation index , to decide if NanoViricides performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.52 |
Modest predictability
NanoViricides has modest predictability. Overlapping area represents the amount of predictability between NanoViricides time series from 31st of October 2025 to 15th of December 2025 and 15th of December 2025 to 29th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of NanoViricides price movement. The serial correlation of 0.52 indicates that about 52.0% of current NanoViricides price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.52 | |
| Spearman Rank Test | 0.43 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, NanoViricides reported net income of (9.47 Million). This is 102.77% lower than that of the Biotechnology sector and 113.52% lower than that of the Health Care industry. The net income for all United States stocks is 101.66% higher than that of the company.
NanoViricides Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NanoViricides' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NanoViricides could also be used in its relative valuation, which is a method of valuing NanoViricides by comparing valuation metrics of similar companies.NanoViricides is currently under evaluation in net income category among its peers.
NanoViricides Fundamentals
| Return On Equity | -0.94 | |||
| Return On Asset | -0.51 | |||
| Current Valuation | 22.82 M | |||
| Shares Outstanding | 21.57 M | |||
| Shares Owned By Insiders | 2.78 % | |||
| Shares Owned By Institutions | 6.64 % | |||
| Number Of Shares Shorted | 458.44 K | |||
| Price To Earning | (6.02) X | |||
| Price To Book | 3.34 X | |||
| EBITDA | (8.72 M) | |||
| Net Income | (9.47 M) | |||
| Cash And Equivalents | 14.07 M | |||
| Cash Per Share | 1.21 X | |||
| Total Debt | 1.31 M | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 34.92 X | |||
| Book Value Per Share | 0.41 X | |||
| Cash Flow From Operations | (8.48 M) | |||
| Short Ratio | 1.36 X | |||
| Earnings Per Share | (0.50) X | |||
| Target Price | 6.5 | |||
| Beta | 1.24 | |||
| Market Capitalization | 23.29 M | |||
| Total Asset | 8.82 M | |||
| Retained Earnings | (148.84 M) | |||
| Working Capital | 364.19 K | |||
| Current Asset | 24.38 M | |||
| Current Liabilities | 6.74 M | |||
| Net Asset | 8.82 M |
About NanoViricides Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NanoViricides's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NanoViricides using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NanoViricides based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether NanoViricides offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NanoViricides' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Nanoviricides Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Nanoviricides Stock:Check out NanoViricides Piotroski F Score and NanoViricides Altman Z Score analysis. For information on how to trade NanoViricides Stock refer to our How to Trade NanoViricides Stock guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Will Stock sector continue expanding? Could NanoViricides diversify its offerings? Factors like these will boost the valuation of NanoViricides. Anticipated expansion of NanoViricides directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every NanoViricides data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding NanoViricides requires distinguishing between market price and book value, where the latter reflects NanoViricides's accounting equity. The concept of intrinsic value—what NanoViricides' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push NanoViricides' price substantially above or below its fundamental value.
It's important to distinguish between NanoViricides' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding NanoViricides should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, NanoViricides' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.